Protective immunity induced by recombinant protein CPSIT_p8 of Chlamydia psittaci

Liang, Mingxing; Wen, Yang; Ran, Ou; Chen, Liesong; Wang, Chuan; Li, Li; Xie, Yanping; Yang, Zaixing; Chen, Chaoqun; Wu, Yimou

doi:10.1007/s00253-016-7494-8

Cited by 20 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results also show GrpE vaccination in the presence of FCA could induce readily detectable Th1 responses; however, there wasn't increased inflammation in response to the infection or reduced pathological changes of the infected site. FCA are known to enhance the immunogenicity of the immunogen, play an immune regulation role, and increase the immune effect of the antigen, which can modulate immune cells and enhance humoral and cellular immune responses in the host (22,46,47). So we conclude that the GrpE protein in the presence of FCA may induce protective Th1 immune response in mice and be considered as an effective vaccine against U. urealyticum infection.…”

Section: Discussionmentioning

confidence: 70%

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

et al. 2020

View full text Add to dashboard Cite

Nucleotide exchange factor (GrpE), a highly conserved antigen, is rapidly expressed and upregulated when Ureaplasma urealyticum infects a host, which could act as a candidative vaccine if it can induce an anti-U. urealyticum immune reaction. Here, we evaluated the vaccine potential of recombinant GrpE protein adjuvanted by Freund's adjuvant (FA), to protect against U. urealyticum genital tract infection in a mouse model. After booster immunization in mice with FA, the GrpE can induced both humoral and cellular immune response after intramuscular injection into BALB/c mice. A strong humoral immune response was detected in the GrpE-immunized mice characterized by production of high titers of antigen-specific serum IgG (IgG1, IgG2a, and IgG3) antibodies. At the same time, the GrpE also induced a Th1-biased cytokine spectrum with high levels of IFN-γ and TNF-α after re-stimulation with immunogen GrpE in vitro, suggesting that GrpE could trigger the Th1 response when used for vaccination in the presence of FA. Although GrpE vaccination in the presence of a Th1-type adjuvant-induced had readily detectable Th1 responses, there wasn't increase inflammation in response to the infection. More importantly, the robust immune responses in mice after immunization with GrpE showed a significantly reduced U. urealyticum burden in cervical tissues. Histopathological analysis confirmed that tissues of GrpE-immunized BALB/c mice were protected against the pathological effects of U. urealyticum infection. In conclusion, this study preliminarily reveals GrpE protein as a promising new candidate vaccine for preventing U. urealyticum reproductive tract infection.

show abstract

Section: Discussionmentioning

confidence: 70%

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The lung homogenates were centrifuged (4°C, 15 mins, 6000 rpm) and inoculated on HeLa 229 cell monolayers after being serially diluted of the supernatants determining the C. psittaci titers. Intracellular inclusions of C. psittaci in the lungs were detected by fluorescence microscopy as described previously 7. The lungs from each mouse were embedded in paraffin for a histopathological assay, sectioned and stained with hematoxylin-eosin (H&E) and an UltraSensitive™SP (Rabbit) IHC Kit (Maixin, China) for the evaluation of inflammatory invasion.…”

Section: Methodsmentioning

confidence: 99%

“…Appropriate candidate antigens (Ags) are one of the crucial factors for the development of Chlamydia vaccine 6. There are many studies that have been done to search protective antigens in animal models, such as C. psittaci major outer membrane protein (MOMP) and plasmid-encoded protein 7–9. Although the protective effects of subunit protein Ags have already been confirmed, the complexity of protection and stability made them far from ideal candidate vaccines.…”

Section: Introductionmentioning

confidence: 99%

<p>Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles–Adjuvanted <em>Chlamydia</em> Vaccine Elicits Elevated Protective Responses In The Lung</p>

Li¹,

Wang²,

Sun³

et al. 2019

IJN

Self Cite

View full text Add to dashboard Cite

Background: Chlamydia psittaci is a zoonotic bacteria closely associated with psittacosis/ ornithosis. Vaccination has been recognized as the best way to inhibit the spread of C. psittaci due to the majority ignored of infections. The optimal Chlamydia vaccine was obstructed by the defect of single immunization route and the lack of availability of nontoxic and valid adjuvants. Methods: In this study, we developed a novel immunization strategy, simultaneous (SIM) intramuscular (IM) and intranasal (IN) administration of a C. psittaci antigens (Ags) adjuvanted with chitosan nanoparticles (CNPs). And SIM-CNPs-Ags were used to determine the different types of immune response and the protective role in vivo. Results: CNPs-Ags with zeta-potential values of 13.12 mV and of 276.1 nm showed excellent stability and optimal size for crossing the mucosal barrier with high 71.7% encapsulation efficiency. SIM-CPN-Ags mediated stronger humoral and mucosal responses by producing meaningfully high levels of IgG and secretory IgA (sIgA) antibodies. The SIM route also led to Ags-specific T-cell responses and increased IFN-γ, IL-2, TNF-α and IL-17A in the splenocyte supernatants. Following respiratory infection with C. psittaci, we found that SIM immunization remarkably reduced bacterial load and the degree of inflammation in the infected lungs and made for a lower level of IFN-γ, TNF-α and IL-6. Furthermore, SIM vaccination with CNPs-Ags had obviously inhibited C. psittaci disseminating to various organs in vivo. Conclusion: SIM immunization with CNPs-adjuvanted C. psittaci Ags may present a novel strategy for the development of a vaccine against the C. psittaci infection.

show abstract

“…These trials utilized recombinant proteins (three trials) or plasmids in different vectors (eukaryotic and viral) (two trials). Results from all five studies observed partial protection from infection and/or disease; however, each utilized a different gene or protein making comparisons difficult (Loots et al, 2006; Qiu et al, 2010; Liu et al, 2015; Liang et al, 2016; Ran et al, 2017).…”

Section: Vaccine Trials For Animal Chlamydial Infectionsmentioning

confidence: 99%

Seventy Years of Chlamydia Vaccine Research – Limitations of the Past and Directions for the Future

2019

View full text Add to dashboard Cite

Chlamydia is a major bacterial pathogen that infects humans, as well as a wide range of animals, including marsupials, birds, cats, pigs, cattle, and sheep. Antibiotics are the only treatment currently available, however, with high rates of re-infection, there is mounting pressure to develop Chlamydia vaccines. In this review, we analyzed how Chlamydia vaccine trials have developed over the past 70 years and identified where future trials need to be focused. There has been a strong bias toward studies targeting C. muridarum and C. trachomatis within mice and a lack of studies matching chlamydial species to their end target host. Even though a large number of specific antigenic targets have been studied, the results from whole-cell vaccine targets show slightly more promising results overall. There has also been a strong bias toward systemic vaccine delivery systems, despite the finding that mucosal delivery systems have shown more promising outcomes. However, the only successful vaccines with matched chlamydial species/infecting host are based on systemic vaccine delivery methods. We highlight the extensive work done with mouse model trials and indicate that whole cell antigenic targets are capable of inducing an effective response, protecting from disease and reducing shedding rates. However, replication of these results using antigen preparations more conducive to commercial vaccine production has proven difficult. To date, the Major Outer Membrane Protein (MOMP) has emerged as the most suitable substitute for whole cell targets and its delivery as a combined systemic and mucosal vaccine is most effective. Finally, although mouse model trials are useful, differences between hosts and infecting chlamydial strains are preventing vaccine formulations from mouse models to be translated into larger animals or intended hosts.

show abstract

Protective immunity induced by recombinant protein CPSIT_p8 of Chlamydia psittaci

Cited by 20 publications

References 30 publications

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

GrpE Immunization Protects Against Ureaplasma urealyticum Infection in BALB/C Mice

<p>Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles–Adjuvanted <em>Chlamydia</em> Vaccine Elicits Elevated Protective Responses In The Lung</p>

Seventy Years of Chlamydia Vaccine Research – Limitations of the Past and Directions for the Future

Contact Info

Product

Resources

About